Interval debulking surgery is not worth the wait: A National Cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy

Objectives: In recent clinical trials, neoadjuvant chemotherapy (NACT) followed by interval debulking surgery was not inferior to primary cytoreductive surgery (PCS) followed by chemotherapy as initial treatment for advanced-stage epithelial ovarian cancer. Better understanding of PCS and NACT outcomes will facilitate patient selection for these treatments. The aim of this study is to compare PCS and NACT surgical and survival outcomes in a large national database.